No Data
No Data
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
CONSUN PHARMA: CLARIFICATION ANNOUNCEMENT
Changes in Hong Kong stocks | Kangchen Pharmaceutical (01681) rose more than 6% and plans to review the special dividend issuance next Friday. The company's profit double increased last year
Kangchen Pharmaceutical (01681) rose more than 6%. As of press release, it rose 6.43% to HK$6.95, with a turnover of HK$10.996 million.
Insiders Were the Key Beneficiaries as Consun Pharmaceutical Group Limited's (HKG:1681) Market Cap Rises to HK$5.2b
Key Insights Consun Pharmaceutical Group's significant insider ownership suggests inherent interests in company's expansion A total of 3 investors have a majority stake in the company with 57% owner
Kangchen Pharmaceutical (01681.HK) plans to hold a board meeting on May 24 to review and approve the special dividend announcement
Glonghui, May 13, 丨 Kangchen Pharmaceutical (01681.HK) announced that the company will hold a board meeting on May 24, 2024 (Friday) to review and approve the issuance of special dividends and handle any other business (if any): if approved by the board of directors, the company will publish the company separately after the board meeting to include details of the special dividend.
Consun Pharmaceutical to Grant About 8.2 Million Share Options Under New Program
Consun Pharmaceutical Group (HKG:1681) plans to grant share options of about 8.2 million shares, representing 10% of the company's total issued shares, according to a Tuesday filing on the Hong Kong b
No Data